Shots:

• The approval was based on the results from the P-III (ELEVATE UC 52) & (ELEVATE UC 12) clinical trials evaluating the safety & efficacy of Velsipity (2mg, QD). Velsipity received the positive CHMP opinion in Dec 2023
• Both studies met tall the 1EPs & 2EPs by depicting a safety profile consistent with the results from previous Velsipity studies. Moreover, the study also depicted an improvement in the total IBD questionnaire score measuring the health-related quality of life
• Velsipity is an oral S1P receptor modulator that functions by selectively binding to S1P receptor subtypes 1, 4 & 5. Earlier in Oct 2023, Velsipity received the US FDA’s approval for the treatment of adults with moderately to severely active UC

Ref: Pfizer | Image: Pfizer 

Realted Posts:-  Pfizer’s Etrasimod Receives the US FDA’s Approval for Adults with Moderately to Severely Active Ulcerative Colitis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com